Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease

A population-based analysis

Brandi Limbago, Gregory E. Fosheim, Valerie Schoonover, Christina E. Crane, Joelle Nadle, Susan Petit, David Heltzel, Susan M. Ray, Lee H. Harrison, Ruth Lynfield, Ghinwa Dumyati, John Townes, William Schaffner, Yi Mu, Scott K. Fridkin

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

This study characterizes 1,984 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2005 and 2006 from normally sterile sites in patients with invasive MRSA infection. These isolates represent a convenience sample of all invasive MRSA cases reported as part of the Active Bacterial Core surveillance system in eight states in the United States. The majority of isolates were from blood (83.8%), joints (4.1%), and bone (4.2%). Isolates were characterized by pulsed-field gel electrophoresis (PFGE); SCCmec typing; susceptibility to 15 antimicrobial agents; and PCR analysis of staphylococcal enterotoxin A (SEA) to SEH, toxic shock syndrome toxin 1, and Panton-Valentine leukocidin. Thirteen established PFGE types were recognized among these isolates, although USA100 and USA300 predominated, accounting for 53.2% and 31.4% of the isolates, respectively. As expected, isolates from hospital onset cases were predominantly USA100, whereas those from community-associated cases were predominantly USA300. USA100 isolates were diverse (Simpson's discriminatory index [DI] = 0.924); generally positive only for enterotoxin D (74.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addition to β-lactam agents. USA300 isolates were less diverse (DI = 0.566), positive for Panton-Valentine leukocidin (96.3%), and resistant to erythromycin (94.1%) and, less commonly, levofloxacin (54.6%), in addition to β-lactam agents. This collection provides a reference collection of MRSA isolates associated with invasive disease, collected in 2005 and 2006 in the United States, for future comparison and ongoing studies.

Original languageEnglish (US)
Pages (from-to)1344-1351
Number of pages8
JournalJournal of Clinical Microbiology
Volume47
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Lactams
Levofloxacin
Pulsed Field Gel Electrophoresis
Erythromycin
Population
Clindamycin
Enterotoxins
Anti-Infective Agents
Joints
Bone and Bones
Polymerase Chain Reaction
Infection
Panton-Valentine leukocidin

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease : A population-based analysis. / Limbago, Brandi; Fosheim, Gregory E.; Schoonover, Valerie; Crane, Christina E.; Nadle, Joelle; Petit, Susan; Heltzel, David; Ray, Susan M.; Harrison, Lee H.; Lynfield, Ruth; Dumyati, Ghinwa; Townes, John; Schaffner, William; Mu, Yi; Fridkin, Scott K.

In: Journal of Clinical Microbiology, Vol. 47, No. 5, 05.2009, p. 1344-1351.

Research output: Contribution to journalArticle

Limbago, B, Fosheim, GE, Schoonover, V, Crane, CE, Nadle, J, Petit, S, Heltzel, D, Ray, SM, Harrison, LH, Lynfield, R, Dumyati, G, Townes, J, Schaffner, W, Mu, Y & Fridkin, SK 2009, 'Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: A population-based analysis', Journal of Clinical Microbiology, vol. 47, no. 5, pp. 1344-1351. https://doi.org/10.1128/JCM.02264-08
Limbago, Brandi ; Fosheim, Gregory E. ; Schoonover, Valerie ; Crane, Christina E. ; Nadle, Joelle ; Petit, Susan ; Heltzel, David ; Ray, Susan M. ; Harrison, Lee H. ; Lynfield, Ruth ; Dumyati, Ghinwa ; Townes, John ; Schaffner, William ; Mu, Yi ; Fridkin, Scott K. / Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease : A population-based analysis. In: Journal of Clinical Microbiology. 2009 ; Vol. 47, No. 5. pp. 1344-1351.
@article{421e8f69ba894d2395448fa309a54143,
title = "Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: A population-based analysis",
abstract = "This study characterizes 1,984 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2005 and 2006 from normally sterile sites in patients with invasive MRSA infection. These isolates represent a convenience sample of all invasive MRSA cases reported as part of the Active Bacterial Core surveillance system in eight states in the United States. The majority of isolates were from blood (83.8{\%}), joints (4.1{\%}), and bone (4.2{\%}). Isolates were characterized by pulsed-field gel electrophoresis (PFGE); SCCmec typing; susceptibility to 15 antimicrobial agents; and PCR analysis of staphylococcal enterotoxin A (SEA) to SEH, toxic shock syndrome toxin 1, and Panton-Valentine leukocidin. Thirteen established PFGE types were recognized among these isolates, although USA100 and USA300 predominated, accounting for 53.2{\%} and 31.4{\%} of the isolates, respectively. As expected, isolates from hospital onset cases were predominantly USA100, whereas those from community-associated cases were predominantly USA300. USA100 isolates were diverse (Simpson's discriminatory index [DI] = 0.924); generally positive only for enterotoxin D (74.5{\%}); and resistant to clindamycin (98.6{\%}), erythromycin (99.0{\%}), and levofloxacin (99.6{\%}), in addition to β-lactam agents. USA300 isolates were less diverse (DI = 0.566), positive for Panton-Valentine leukocidin (96.3{\%}), and resistant to erythromycin (94.1{\%}) and, less commonly, levofloxacin (54.6{\%}), in addition to β-lactam agents. This collection provides a reference collection of MRSA isolates associated with invasive disease, collected in 2005 and 2006 in the United States, for future comparison and ongoing studies.",
author = "Brandi Limbago and Fosheim, {Gregory E.} and Valerie Schoonover and Crane, {Christina E.} and Joelle Nadle and Susan Petit and David Heltzel and Ray, {Susan M.} and Harrison, {Lee H.} and Ruth Lynfield and Ghinwa Dumyati and John Townes and William Schaffner and Yi Mu and Fridkin, {Scott K.}",
year = "2009",
month = "5",
doi = "10.1128/JCM.02264-08",
language = "English (US)",
volume = "47",
pages = "1344--1351",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease

T2 - A population-based analysis

AU - Limbago, Brandi

AU - Fosheim, Gregory E.

AU - Schoonover, Valerie

AU - Crane, Christina E.

AU - Nadle, Joelle

AU - Petit, Susan

AU - Heltzel, David

AU - Ray, Susan M.

AU - Harrison, Lee H.

AU - Lynfield, Ruth

AU - Dumyati, Ghinwa

AU - Townes, John

AU - Schaffner, William

AU - Mu, Yi

AU - Fridkin, Scott K.

PY - 2009/5

Y1 - 2009/5

N2 - This study characterizes 1,984 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2005 and 2006 from normally sterile sites in patients with invasive MRSA infection. These isolates represent a convenience sample of all invasive MRSA cases reported as part of the Active Bacterial Core surveillance system in eight states in the United States. The majority of isolates were from blood (83.8%), joints (4.1%), and bone (4.2%). Isolates were characterized by pulsed-field gel electrophoresis (PFGE); SCCmec typing; susceptibility to 15 antimicrobial agents; and PCR analysis of staphylococcal enterotoxin A (SEA) to SEH, toxic shock syndrome toxin 1, and Panton-Valentine leukocidin. Thirteen established PFGE types were recognized among these isolates, although USA100 and USA300 predominated, accounting for 53.2% and 31.4% of the isolates, respectively. As expected, isolates from hospital onset cases were predominantly USA100, whereas those from community-associated cases were predominantly USA300. USA100 isolates were diverse (Simpson's discriminatory index [DI] = 0.924); generally positive only for enterotoxin D (74.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addition to β-lactam agents. USA300 isolates were less diverse (DI = 0.566), positive for Panton-Valentine leukocidin (96.3%), and resistant to erythromycin (94.1%) and, less commonly, levofloxacin (54.6%), in addition to β-lactam agents. This collection provides a reference collection of MRSA isolates associated with invasive disease, collected in 2005 and 2006 in the United States, for future comparison and ongoing studies.

AB - This study characterizes 1,984 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2005 and 2006 from normally sterile sites in patients with invasive MRSA infection. These isolates represent a convenience sample of all invasive MRSA cases reported as part of the Active Bacterial Core surveillance system in eight states in the United States. The majority of isolates were from blood (83.8%), joints (4.1%), and bone (4.2%). Isolates were characterized by pulsed-field gel electrophoresis (PFGE); SCCmec typing; susceptibility to 15 antimicrobial agents; and PCR analysis of staphylococcal enterotoxin A (SEA) to SEH, toxic shock syndrome toxin 1, and Panton-Valentine leukocidin. Thirteen established PFGE types were recognized among these isolates, although USA100 and USA300 predominated, accounting for 53.2% and 31.4% of the isolates, respectively. As expected, isolates from hospital onset cases were predominantly USA100, whereas those from community-associated cases were predominantly USA300. USA100 isolates were diverse (Simpson's discriminatory index [DI] = 0.924); generally positive only for enterotoxin D (74.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxacin (99.6%), in addition to β-lactam agents. USA300 isolates were less diverse (DI = 0.566), positive for Panton-Valentine leukocidin (96.3%), and resistant to erythromycin (94.1%) and, less commonly, levofloxacin (54.6%), in addition to β-lactam agents. This collection provides a reference collection of MRSA isolates associated with invasive disease, collected in 2005 and 2006 in the United States, for future comparison and ongoing studies.

UR - http://www.scopus.com/inward/record.url?scp=66149156410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149156410&partnerID=8YFLogxK

U2 - 10.1128/JCM.02264-08

DO - 10.1128/JCM.02264-08

M3 - Article

VL - 47

SP - 1344

EP - 1351

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 5

ER -